W Horne S, Johnson LM, Ketas TJ, Klasse PJohan, Lu M, Moore JP, Gellman SH.
2009.
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.. Proc Natl Acad Sci U S A. 106(35):14751-6.
Kent A, Mon KJoy Yee, Hutchins Z, Putzel G, Zhigarev D, Grier A, Jia B, Kortlever RM, Barbet G, Evan GI et al..
2025.
A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis.. Nat Immunol. 26(1):53-67.
Vaubourgeix J, Lin G, Dhar N, Chenouard N, Jiang X, Botella H, Lupoli T, Mariani O, Yang G, Ouerfelli O et al..
2015.
Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells.. Cell Host Microbe. 17(2):178-90.
Vaubourgeix J, Lin G, Dhar N, Chenouard N, Jiang X, Botella H, Lupoli T, Mariani O, Yang G, Ouerfelli O et al..
2015.
Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells.. Cell Host Microbe. 17(2):178-90.
Carter LM, Kafsack BFC, Llinás M, Mideo N, Pollitt LC, Reece SE.
2013.
Stress and sex in malaria parasites: Why does commitment vary? Evol Med Public Health. 2013(1):135-47.
Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW.
2010.
Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.. J Biol Chem. 285(47):36456-70.
Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW.
2010.
Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.. J Biol Chem. 285(47):36456-70.
Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D et al..
2022.
Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.. J Med Chem. 65(9):6903-6925.
Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D et al..
2022.
Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.. J Med Chem. 65(9):6903-6925.
Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D et al..
2022.
Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.. J Med Chem. 65(9):6903-6925.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.